Members

  First name: Veronique
  Last name: Joly
  Function: Infectious disease physician - Researcher
  Position: Hospital practitioner
  Email: veronique.joly
._
_.
aphp.fr

Research interest


My main centers of interest are the follow-up of HIV infected patients, communotary bacterial infection management and tuberculosis. I am working as a hospital practitioner at the Universitary Hospital Bichat Claude Bernard in Paris and I am responsible of a 18 beds unit in the Infectious Diseases department. I am involved in the Dat'AIDS scientific committee and in the Esther program for the South. As an infectious diseases specialist I was involved in diagnosis and treatment of HIV since the beginning of the epidemic and my main research fields are based on: (i) evaluation of therapeutic strategies for HIV and (ii) study of predictive factors of virological response (reservoir, resistance orpharmacological markers). I was the principal investigators of several ANRS clinical trials studying antiretroviral therapy efficiency or toxicity and, currently, of the ANRS 167 assay, a pilot study evaluating the safety of a switch by a dolutegravir-lamivudine bitherapy.

Education

Degree

1992: Ph. D. in Infectious Diseases Pharmacology, Paris 7 University
1988: Molecular Biology course at Pasteur Institute
1986: Medical Doctor (UER X. Bichat)
1985: Master in Pharmacology, Paris 11 University

Academic positions

Since 1996: Hospital Practioner, Hôpital Bichat-Claude Bernard, Paris
1992-1996: Universitary Hospital Practicioner, Internal Medicine, Hôpital Bichat, Paris
1988-1992: Assistant professor, Internal Medicine, Hôpital Bichat, Paris
1981-1986: Residency, Assistance Publique des Hôpitaux de Paris

List of the main publications

Senard O, Burdet C, Visseaux B, Charpentier C, Le Gac S, Julia Z, Lariven S, Descamps D, Yazdanpanah Y, Yeni P, Joly V
Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study.
AIDS Res Hum Retroviruses 2017, 33, 11-16.

Charpentier C, Lê MP, Joly V, Visseaux B, Lariven S, Phung B, Yéni P, Yazdanpanah Y, Descamps D, Peytavin G, Landman R
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.
PloS One 2015, 10, e0134430.

Caseris M, Houhou N, Longuet P, Rioux C, Lepeule R, Choquet C, Yazdanpanah Y, Yeni P, Joly V
French 2010-2011 measles outbreak in adults: report from a Parisian teaching hospital.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2014, 20, O242-244.

Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P, S1ATG
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Antimicrobial Agents and Chemotherapy 2013, 57, 758-765.


Exhaustive list of publications

2022


Pansu N, Le Moing V, Poizot-Martin I, Joly V, Allavena C, Hocqueloux L, Duvivier C, Lourenco J, Jovelin T, Reynes J, Makinson A
Pneumocystis jirovecii Pneumonia and Toxoplasmosis in PWH With HIV-Controlled Disease Treated for Solid Malignancies: A DAT'AIDS Study.
Open Forum Infectious Diseases 2022, 9, ofac109.

Chotard E, Jacquier H, Bart G, Richette P, Rioux C, Joly V, Goossens J, Palazzo E, Forien M, Jelin G, Yazdanpanah Y, Dieudé P, Le Goff B, Ottaviani S
MRI Features Associated With the Detection of Microbial Pathogens by CT-Guided Biopsy in Septic Spondylodiscitis.
Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases 2022, 28, e189-e194.

2021


Cohen Aubart F, Lhote R, Hertig A, Noel N, Costedoat-Chalumeau N, Cariou A, Meyer G, Cymbalista F, de Prost N, Pottier P, Joly L, Lambotte O, Renaud MC, Badoual C, Braun M, Palombi O, Duguet A, Roux D
Progressive clinical case-based multiple-choice questions: An innovative way to evaluate and rank undergraduate medical students.
La Revue De Medecine Interne 2021, 42, 302-309.

Charpentier C, Storto A, Soulié C, Ferré VM, Wirden M, Joly V, Lambert-Niclot S, Palich R, Morand-Joubert L, Landman R, Lacombe K, Katlama C, Ghosn J, Marcelin AG, Calvez V, Descamps D
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
The Journal of Antimicrobial Chemotherapy 2021

Charpentier C, Storto A, Soulié C, Ferré VM, Wirden M, Joly V, Lambert-Niclot S, Palich R, Morand-Joubert L, Landman R, Lacombe K, Katlama C, Ghosn J, Marcelin AG, Calvez V, Descamps D
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2983-2987.

Deschanvres C, Reynes J, Lamaury I, Rey D, Palich R, Bani-Sadr F, Robineau O, Duvivier C, Hocqueloux L, Cuzin L, Joly V, Raffi F, Cabie A, Allavena C, DSG
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
The Journal of Antimicrobial Chemotherapy 2021, 77, 196-204.

Lahens A, Mullaert J, Gressens S, Gault N, Flamant M, Deconinck L, Joly V, Yazdanpanah Y, Lescure FX, Vidal-Petiot E
Association between renin-angiotensin-aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment.
Journal of Hypertension 2021, 39, 367-375.

2020


Pichon M, Joly V, Argy N, Houze S, Bretagne S, Alanio A, Wassef M, Verillaud B, Yazdanpanah Y
Aspergillus flavus malignant external otitis in a diabetic patient: case report and literature review.
Infection 2020, 48, 193-203.

Isernia V, Julia Z, Le Gac S, Bachelard A, Landman R, Lariven S, Joly V, Deconinck L, Rioux C, Lescure X, Yazdanpanah Y, Ghosn J
SARS-COV2 infection in 30 HIV-infected patients followed-up in a French University Hospital.
International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2020, 101, 49-51.

Jary A, Leducq V, Desire N, Petit H, Palich R, Joly V, Canestri A, Gothland A, Lambert-Niclot S, Surgers L, Amiel C, Descamps D, Spano JP, Katlama C, Calvez V, Marcelin AG
New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies.
The Journal of Infectious Diseases 2020, 222, 1320-1328.

Charpentier C, Peytavin G, Raffi F, Burdet C, Landman R, Lê MP, Katlama C, Collin G, Benalycherif A, Cabie A, Mentré F, Yazdanpanah Y, Descamps D, Joly V
Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
The Journal of Antimicrobial Chemotherapy 2020, 75, 1611-1617.

2019


Pugliese P, Joly V, Valantin M, Cotte L, Huleux T, Allavena C, Reynes J, Poizot-Martin I, Bani-Sadr F, Cuzin L
Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France.
Médecine et Maladies Infectieuses 2019, 49, 264-269.

Peiffer-Smadja N, Harent S, Messeca C, Lechapt-Zalcman E, Yazdanpanah Y, Joly V
A case of thoracic actinomycosis presenting as sudden paraplegia.
Revue Neurologique 2019, 175, 89-92.

Parisey M, Louni F, Bouvet E, Landman R, Charpentier C, Lariven S, Joly V, Villemant A, Mackoumbou-Nkouka C, Yazdanpanah Y, Burdet C
HIV Infection in North African Patients.
AIDS research and human retroviruses 2019, 35, 628-633.

Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y, LSG
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
The Journal of Antimicrobial Chemotherapy 2019, 74, 739-745.

Perrier M, Castain L, Regad L, Todesco E, Landman R, Visseaux B, Yazdanpanah Y, Rodriguez C, Joly V, Calvez V, Marcelin AG, Descamps D, Charpentier C
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1679-1692.

Castain L, Perrier M, Charpentier C, Palich R, Desire N, Wirden M, Descamps D, Sayon S, Landman R, Valantin MA, Joly V, Peytavin G, Yazdanpanah Y, Katlama C, Calvez V, Marcelin AG, Todesco E
New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
The Journal of Antimicrobial Chemotherapy 2019, 74, 2019-2023.

Gantner P, Cotte L, Allavena C, Bani-Sadr F, Huleux T, Duvivier C, Valantin MA, Jacomet C, Joly V, Chéret A, Pugliese P, Delobel P, Cabié A, Rey D, ftDSG, Huang JF
Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.
PLOS ONE 2019, 14, e0215464.

2018


Cheminet G, Kapel N, Bleibtreu A, Sadou-Yaye H, Bellanger A, Duval X, Joly F, Fantin B, de Lastours V, FGfFMT(
Faecal microbiota transplantation with frozen capsules for relapsing Clostridium difficile infections: the first experience from 15 consecutive patients in France.
The Journal of Hospital Infection 2018, 100, 148-151.

Bleibtreu A, Grall N, Laissy JP, Rioux C, Strukov A, Lariven S, Yeni P, Yazdanpanah Y, Joly V
Contribution of brain imaging to the diagnosis of intracranial tuberculoma and other brain lesions in patients presenting with miliary tuberculosis.
Medecine Et Maladies Infectieuses 2018, 48, 533-539.

Arikawa S, Rollins N, Jourdain G, Humphrey J, Kourtis AP, Hoffman I, Essex M, Farley T, Coovadia HM, Gray G, Kuhn L, Shapiro R, Leroy V, Bollinger RC, Onyango-Makumbi C, Lockman S, Marquez C, Doherty T, Dabis F, Mandelbrot L, Le Coeur S, Rolland M, Joly P, Newell ML, Becquet R
Contribution of Maternal Antiretroviral Therapy and Breastfeeding to 24-Month Survival in Human Immunodeficiency Virus-Exposed Uninfected Children: An Individual Pooled Analysis of African and Asian Studies.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2018, 66, 1668-1677.

Melliez H, Mary-Krause M, Bocket L, Guiguet M, Abgrall S, De Truchis P, Katlama C, Martin-Blondel G, Henn A, Revest M, Robineau O, Khuong-Josses MA, Canestri A, De Castro N, Joly V, Mokhtari S, Risso K, Gasnault J, Costagliola D, FHDoH(C
Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4).
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2018

Mariaggi AA, Péré H, Perrier M, Visseaux B, Collin G, Veyer D, Hingrat QL, Ferré VM, Joly V, Couvelard A, Bucau M, Davitian C, Descamps D, Abramowitz L, Charpentier C
Presence of HPV APOBEC-related Minority Variants in HPV16 Genomes from Anal and Cervical Samples but not in HPV52 and HPV58.
The Journal of Infectious Diseases 2018

Perrier M, Visseaux B, Landman R, Joly V, Todesco E, Yazdanpanah Y, Calvez V, Marcelin AG, Descamps D, Charpentier C
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
The Journal of Antimicrobial Chemotherapy 2018, 73, 173-176.

Charpentier C, Peytavin G, Lê MP, Joly V, Cabras O, Perrier M, Le Gac S, Phung B, Yazdanpanah Y, Descamps D, Landman R
High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.
The Journal of Antimicrobial Chemotherapy 2018, 73, 1665-1671.

Costagliola D, Potard V, Lang S, Abgrall S, Duvivier C, Fischer H, Joly V, Lacombe JM, Valantin MA, Mary-Krause M, Rozenberg S, FAC
Impact of antiretroviral drugs on fracture risk in HIV-infected individuals: A case-control study nested within the French Hospital Database on HIV (FHDH-ANRS CO4).
Journal of Acquired Immune Deficiency Syndromes (1999) 2018

Nassereddine H, Charpentier C, Bucau M, Joly V, Bienvenu L, Davitian C, Abramowitz L, Benabderrahmane D, Kotelevets L, Chastre E, Lehy T, Walker F
Interest of cytology combined with Xpert® HPV and Anyplex® II HPV28 Detection human papillomavirus (HPV) typing: differential profiles of anal and cervical HPV lesions in HIV-infected patients on antiretroviral therapy.
HIV medicine 2018

Jary A, Leducq V, Palich R, Gothland A, Descamps D, Joly V, Lambert-Niclot S, Amiel C, Canestri A, Mirand A, Gault E, Vabret A, Valantin MA, Katlama C, Calvez V, Dupin N, Spano JP, Marcelin AG
Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases.
Journal of Clinical Microbiology 2018, 56,

Allavena C, Hanf M, Rey D, Duvivier C, BaniSadr F, Poizot-Martin I, Jacomet C, Pugliese P, Delobel P, Katlama C, Joly V, Chidiac C, Dournon N, Merrien D, May T, Reynes J, Gagneux-Brunon A, Chirouze C, Huleux T, Cabié A, Raffi F, Dsg
Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients.
PloS One 2018, 13, e0203895.

2017


Welfringer A, Vuong V, Argy N, Chochillon C, Deschamps L, Rollin G, Harent S, Joly V, Vindrios W, Descamps V
A rare fungal infection: Phaehyphomycosis due to Veronaea botryosa and review of literature.
Medical Mycology Case Reports 2017, 15, 21-24.

Pichon M, Mikail N, Ben Ali K, Rouzet F, Burdet C, Yazdanpanah Y, Joly V, Lepage L, Sarda-Mantel L
18FDG-PET/CT: a useful tool for the management of patients in infectious diseases.
Infect Dis (Lond) 2017, 49, 155-157.

Senard O, Burdet C, Visseaux B, Charpentier C, Le Gac S, Julia Z, Lariven S, Descamps D, Yazdanpanah Y, Yeni P, Joly V
Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study.
AIDS Res Hum Retroviruses 2017, 33, 11-16.

Madelain V, Le MP, Champenois K, Charpentier C, Landman R, Joly V, Yeni P, Descamps D, Yazdanpanah Y, Peytavin G
Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1137-1146.

Perrier M, Charpentier C, Peytavin G, Lê M, Blondel L, Visseaux B, Joly V, Pinto A, Matheron S, Yazdanpanah Y, Descamps D, Landman R
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1745-1751.

Perrier M, Bertine M, Le Hingrat Q, Joly V, Visseaux B, Collin G, Landman R, Yazdanpanah Y, Descamps D, Charpentier C
Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2954-2955.

Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C, DSG
Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.
The Journal of Antimicrobial Chemotherapy 2017, 72, 3425-3434.

Lebrun D, Hentzien M, Cuzin L, Rey D, Joly V, Cotte L, Allavena C, Dellamonica P, Servettaz A, Bani-Sadr F, atDsg
Epidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort.
AIDS (London, England) 2017, 31, 2159-2166.

Dutertre M, Cuzin L, Demonchy E, Puglièse P, Joly V, Valantin MA, Cotte L, Huleux T, Delobel P, Martin-Blondel G, DSG
Initiation of Antiretroviral Therapy Containing Integrase Inhibitors Increases the Risk of IRIS Requiring Hospitalization.
Journal of Acquired Immune Deficiency Syndromes (1999) 2017, 76, e23-e26.

Gantner P, Cuzin L, Allavena C, Cabie A, Pugliese P, Valantin MA, Bani-Sadr F, Joly V, Ferry T, Poizot-Martin I, Garraffo R, Peytavin G, Fafi-Kremer S, Rey D, Dsg
Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.
HIV medicine 2017, 18, 704-708.

2016


Slama L, Landman R, Assoumou L, Benalycherif A, Samri A, Joly V, Pialoux G, Valin N, Cabié A, Duvivier C, Lambert-Niclot S, Marcelin AG, Peytavin G, Costagliola D, Girard PM, I0DSG
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
The Journal of Antimicrobial Chemotherapy 2016, 71, 2252–2261.

Diallo YL, Ollivier V, Joly V, Faille D, Catalano G, Jandrot-Perrus M, Rauch A, Yeni P, Ajzenberg N
Abacavir has no prothrombotic effect on platelets in vitro.
The Journal of Antimicrobial Chemotherapy 2016, 71, 3506–3509.

Morel V, Joly D, Villatte C, Dubray C, Durando X, Daulhac L, Coudert C, Roux D, Pereira B, Pickering G
Memantine before Mastectomy Prevents Post-Surgery Pain: A Randomized, Blinded Clinical Trial in Surgical Patients.
PloS One 2016, 11, e0152741.

2015


Pichon M, Savatovsky J, Lamirel C, Joly V, Moulignier A
Isolated blepharoptosis may point to HIV-associated Burkitt's lymphoma.
Acta Neurologica Belgica 2015, 115, 833–835.

Caseris M, Burdet C, Lepeule R, Houhou N, Yeni P, Yazdanpanah Y, Joly V
[An update on measles].
La Revue De Medecine Interne 2015, 36, 339-345.

Deconinck L, Yazdanpanah Y, Gilson RJ, Melliez H, Viget N, Joly V, Sabin CA
Time to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study.
HIV medicine 2015, 16, 219-229.

Charpentier C, Lê MP, Joly V, Visseaux B, Lariven S, Phung B, Yéni P, Yazdanpanah Y, Descamps D, Peytavin G, Landman R
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.
PloS One 2015, 10, e0134430.

Pommier JD, Ben Lasfar N, Van Grunderbeeck N, Burdet C, Laouénan C, Rioux C, Pierre-Audigier C, Meybeck A, Choudat L, Benchikh A, Nguyen S, Bouvet E, Yeni P, Yazdanpanah Y, Joly V
Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients.
Infectious Diseases (London, England) 2015, 47, 725-731.

Loubet P, Lescure FX, Lepage L, Kirsch M, Armand-Lefevre L, Bouadma L, Lariven S, Duval X, Yazdanpanah Y, Joly V
Endocarditis due to gram-negative bacilli at a French teaching hospital over a 6-year period: clinical characteristics and outcome.
Infectious Diseases (London, England) 2015, 47, 889-895.

2014


Charpentier C, Joly V, Ghosn J, Yeni P, Raffi F, Descamps D, Morand-Joubert L
Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen.
The Journal of Antimicrobial Chemotherapy 2014, 69, 2588–2590.

Charpentier C, Choquet M, Joly V, Yeni P, Visseaux B, Caseris M, Brun-Vézinet F, Yazdanpanah Y, Peytavin G, Descamps D, Landman R
Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.
The Journal of Antimicrobial Chemotherapy 2014, 69, 2819-2825.

Caseris M, Houhou N, Longuet P, Rioux C, Lepeule R, Choquet C, Yazdanpanah Y, Yeni P, Joly V
French 2010-2011 measles outbreak in adults: report from a Parisian teaching hospital.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2014, 20, O242-244.

2013


Steff M, Joly V, Di Lucca J, Feldman J, Burg S, Sarda-Mantel L, Peytavin G, Marinho E, Crickx B, Raymond E, Lariven S, Maubec E
Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma.
JAMA dermatology 2013, 149, 1319-1322.

Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D, A1ATSG
Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.
The Journal of Antimicrobial Chemotherapy 2013, 68, 690-696.

Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P, S1ATG
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Antimicrobial Agents and Chemotherapy 2013, 57, 758-765.

Charpentier C, Champenois K, Gervais A, Landman R, Joly V, Le Gac S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, Yazdanpanah Y
Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients.
PloS One 2013, 8, e59205.

2012


de Montmollin E, Corcos O, Noussair L, Leflon-Guibout V, Belmatoug N, Joly F, Lefort A
Retroperitoneal abscesses due to Nocardia farcinica: report of two cases in patients with malnutrition.
Infection 2012, 40, 93-96.

Charpentier C, Landman R, Laouénan C, Joly V, Hamet G, Damond F, Brun-Vézinet F, Mentré F, Descamps D, Yeni P
Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.
The Journal of Antimicrobial Chemotherapy 2012, 67, 2231-2235.

Groh M, Faussart A, Villena I, Ajzenberg D, Carme B, Demar M, Joly V, Houze S, Simon S, Aubert D, Charlois-Ou C, Yeni P
Acute lung, heart, liver, and pancreatic involvements with hyponatremia and retinochoroiditis in a 33-year-old French Guianan patient.
PLoS neglected tropical diseases 2012

2004


Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.
Antimicrobial Agents and Chemotherapy 2004, 48, 172-175.

2003


Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D, CEGftFHDoH
Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2003, 37, 1517-1526.